NotesFAQContact Us
Collection
Advanced
Search Tips
Showing all 13 results Save | Export
Sensitivity of the Modified Children's Yale-Brown Obsessive Compulsive Scale to Detect Change: Results from Two Multi-Site Trials
Peer reviewed Peer reviewed
Direct linkDirect link
Scahill, Lawrence; Sukhodolsky, Denis G.; Anderberg, Emily; Dimitropoulos, Anastasia; Dziura, James; Aman, Michael G.; McCracken, James; Tierney, Elaine; Hallett, Victoria; Katz, Karol; Vitiello, Benedetto; McDougle, Christopher – Autism: The International Journal of Research and Practice, 2016
Repetitive behavior is a core feature of autism spectrum disorder. We used 8-week data from two federally funded, multi-site, randomized trials with risperidone conducted by the Research Units on Pediatric Psychopharmacology Autism Network to evaluate the sensitivity of the Children's Yale-Brown Obsessive Compulsive Scale modified for autism…
Descriptors: Autism, Pervasive Developmental Disorders, Scores, Networks
Brief Report: Social Disability in Autism Spectrum Disorder--Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials
Peer reviewed Peer reviewed
Direct linkDirect link
Scahill, Lawrence; Hallett, Victoria; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; McCracken, James T.; Tierney, Elaine; Deng, Yanhong; Dziura, James; Vitiello, Benedetto – Journal of Autism and Developmental Disorders, 2013
There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to…
Descriptors: Autism, Pharmacology, Effect Size, Pervasive Developmental Disorders
Selecting an Antidepressant for the Treatment of Pediatric Depression
Peer reviewed Peer reviewed
Direct linkDirect link
Kratochvil, Christopher J.; Vitiello, Benedetto; Brent, David; Bostic, Jeff Q.; Naylor, Michael W. – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which there are no adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid…
Descriptors: Pharmacology, Cognitive Processes, Pediatrics, Depression (Psychology)
Pharmacogenetics of Methylphenidate Response in Preschoolers with ADHD
Peer reviewed Peer reviewed
Direct linkDirect link
McGough, James; McCracken, James; Swanson, James; Riddle, Mark; Kollins, Scott; Greenhill, Laurence; Abikoff, Howard; Davies, Mark; Chuang, Shirley; Wigal, Tim; Wigal, Sharon; Posner, Kelly; Skrobala, Anne; Kastelic, Elizabeth; Ghuman, Jaswinder; Cunningham, Charles; Shigawa, Sharon; Moyzis, Robert; Vitiello, Benedetto – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: The authors explored genetic moderators of symptom reduction and side effects in methylphenidate-treated preschool-age children diagnosed with attention-deficit/hyperactivity disorder (ADHD). Method: DNA was isolated from 81 subjects in a double-blind, placebo-controlled, crossover methylphenidate titration. Parents and teachers…
Descriptors: Hyperactivity, Genetics, Attention Deficit Disorders, Drug Therapy
Consensus Report on Impulsive Aggression as a Symptom across Diagnostic Categories in Child Psychiatry: Implications for Medication Studies
Peer reviewed Peer reviewed
Direct linkDirect link
Jensen, Peter S.; Youngstrom, Eric A.; Steiner, Hans; Findling, Robert L.; Meyer, Roger E.; Malone, Richard P.; Carlson, Gabrielle A.; Coccaro, Emil F.; Aman, Michael G.; Blair, James; Dougherty, Donald; Ferris, Craig; Flynn, Laurie; Green, Evelyn; Hoagwood, Kimberly; Hutchinson, Janice; Laughren, Tom; Leve, Leslie D.; Novins, Douglas K.; Vitiello, Benedetto – Journal of the American Academy of Child & Adolescent Psychiatry, 2007
Objective: To determine whether impulsive aggression (IA) is a meaningful clinical construct and to ascertain whether it is sufficiently similar across diagnostic categories, such that parallel studies across disorders might constitute appropriate evidence for pursuing indications. If so, how should IA be assessed, pharmacological studies…
Descriptors: Psychiatry, Public Health, Ethics, Clinical Experience
Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers with ADHD
Peer reviewed Peer reviewed
Direct linkDirect link
Greenhill, Laurence; Kollins, Scott; Abikoff, Howard; McCracken, James; Riddle, Mark; Swanson, James; McGough, James; Wigal, Sharon; Wigal, Tim; Vitiello, Benedetto; Skrobala, Anne; Posner, Kelly; Ghuman, Jaswinder; Cunningham, Charles; Davies, Mark; Chuang, Shirley; Cooper, Tom – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: The Preschool ADHD Treatment Study (PATS) was a NIMH-funded, six-center, randomized, controlled trial to determine the efficacy and safety of immediate-release methylphenidate (MPH-IR), given t.i.d. to children ages 3 to 5.5 years with attention-deficit/hyperactivity disorder (ADHD). Method: The 8-phase, 70-week PATS protocol included…
Descriptors: Safety, Rating Scales, Hyperactivity, Effect Size
Stimulant-Related Reductions of Growth Rates in the PATS
Peer reviewed Peer reviewed
Direct linkDirect link
Swanson, James; Greenhill, Laurence; Wigal, Tim; Kollins, Scott; Stehli, Annamarie; Davies, Mark; Chuang, Shirley; Vitiello, Benedetto; Skrobala, Anne; Posner, Kelly; Abikoff, Howard; Oatis, Melvin; McCracken, James; McGough, James; Riddle, Mark; Ghuman, Jaswinder; Cunningham, Charles; Wigal, Sharon – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To investigate growth of children with attention-deficit/hyperactivity disorder (ADHD) in the Preschool ADHD Treatment Study (PATS) before and after initiation of treatment with methylphenidate at titrated doses (average, 14.2 mg/day) administered three times daily, 7 days/week for approximately equal to 1 year. Method: The heights and…
Descriptors: Stimulants, Hyperactivity, Attention Deficit Disorders, Body Height
Child and Adolescent Psychopharmacology in the New Millennium: A Workshop for Academia, Industry, and Government
Peer reviewed Peer reviewed
Direct linkDirect link
Deveaugh-Geiss, Joseph; March, John; Shapiro, Mark; Andreason, Paul J.; Emslie, Graham; Ford, Lisa M.; Greenhill, Laurence; Murphy, Dianne; Prentice, Ernest; Roberts, Rosemary; Silva, Susan; Swanson, James M.; van Zwieten-Boot, Barbara; Vitiello, Benedetto; Wagner, Karen Dineen; Mangum, Barry – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To give academic researchers, government officials, and industry scientists an opportunity to assess the state of pediatric psychopharmacology and identify challenges facing professionals in the field. Method: Increased federal spending and the introduction of pediatric exclusivity led to large increases in pediatric psychopharmacology…
Descriptors: Safety, Psychiatry, Mental Disorders, Research Needs
Safety and Tolerability of Methylphenidate in Preschool Children with ADHD
Peer reviewed Peer reviewed
Direct linkDirect link
Wigal, Tim; Greenhill, Laurence; Chuang, Shirley; McGough, James; Vitiello, Benedetto; Skrobala, Anne; Swanson, James; Wigal, Sharon; Abikoff, Howard; Kollins, Scott; McCracken, James; Riddle, Mark; Posner, Kelly; Ghuman, Jaswinder; Davies, Mark; Thorp, Ben; Stehli, Annamarie – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To report on the safety and tolerability of methylphenidate (MPH) 3- to 5-year-old children with attention-deficit/hyperactivity disorder (ADHD) during 1 year of treatment. Method: Exactly 183 children (3-5 years old) entered a treatment study of MPH, consisting of a 1-week open-label lead-in (n = 183); a 5-week placebo-controlled,…
Descriptors: Safety, Maintenance, Preschool Children, Hyperactivity
Remission and Residual Symptoms after Short-Term Treatment in the Treatment of Adolescents with Depression Study (TADS)
Peer reviewed Peer reviewed
Direct linkDirect link
Kennard, Betsy; Silva, Susan; Vitiello, Benedetto; Curry, John; Kratochvil, Christopher; Simons, Anne; Hughes, Jennifer; Feeny, Norah; Weller, Elizabeth; Sweeney, Michael; Reinecke, Mark; Pathak, Sanjeev; Ginsburg, Golda; Emslie, Graham; March, John – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To ascertain remission rates in depressed youth participating in the Treatment for Adolescents With Depression Study (TADS), a multisite clinical trial that randomized 439 adolescents with major depressive disorder (MDD) to a 12-week treatment of fluoxetine (FLX), cognitive-behavioral therapy (CBT), their combination (COMB), or clinical…
Descriptors: Adolescents, Depression (Psychology), Outcomes of Treatment, Symptoms (Individual Disorders)
Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders
Peer reviewed Peer reviewed
Direct linkDirect link
Scahill, Lawrence; McDougle, Christopher J.; Williams, Susan K.; Dimitropoulos, Anastasia; Aman, Michael G.; McCracken, James T.; Tierney, Elaine; Arnold, L. Eugene; Cronin, Pegeen; Grados, Marco; Ghuman, Jaswinder; Koenig, Kathleen; Lam, Kristen S. L.; McGough, James; Posey, David J.; Ritz, Louise; Swiezy, Naomi B.; Vitiello, Benedetto – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To examine the psychometric properties of the Children's Yale-Brown Obsessive Compulsive Scales (CYBOCS) modified for pervasive developmental disorders (PDDs). Method: Raters from five Research Units on Pediatric Psychopharmacology (RUPP) Autism Network were trained to reliability. The modified scale (CYBOCS-PDD), which contains only…
Descriptors: Children, Severity (of Disability), Test Reliability, Behavior Disorders
The Treatment for Adolescents with Depression Study (TADS): Methods and Message at 12 Weeks
Peer reviewed Peer reviewed
Direct linkDirect link
March, John; Silva, Susan; Vitiello, Benedetto – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Funded by the National Institute of Mental Health, the Treatment for Adolescents With Depression Study (TADS) is intended to evaluate the short-term (12 weeks) and longer-term (36 weeks) effectiveness of four treatments for adolescents with DSM-IV major depressive disorder: clinical management with fluoxetine (FLX), cognitive-behavioral therapy…
Descriptors: Patients, Adolescents, Public Health, Quality of Life
Treatment for Adolescents with Depression Study (TADS): Safety Results
Peer reviewed Peer reviewed
Direct linkDirect link
Emslie, Graham; Kratochvil, Christopher; Vitiello, Benedetto; Silva, Susan; Mayes, Taryn; McNulty, Steven; Weller, Elizabeth; Waslick, Bruce; Casat, Charles; Walkup, John; Pathak, Sanjeev; Rohde, Paul; Posner, Kelly; March, John – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To compare the rates of physical, psychiatric, and suicide-related events in adolescents with MDD treated with fluoxetine alone (FLX), cognitive-behavioral therapy (CBT), combination treatment (COMB), or placebo (PBO). Method: Safety assessments included adverse events (AEs) collected by spontaneous report, as well as systematic…
Descriptors: Safety, Patients, Adolescents, Suicide